PPARG and cancer: In accordance, we found that numerous E3-skipped variants were differentially expressed between paired tumor and adjacent normal tissues for most patients with cancer, and that E3 skipping is modulated by the PPARγ activator pioglitazone which contributes to cell differentiation and tumorigenesis [40], [41], [47].